Orchard Therapeutics PLC (NASDAQ:ORTX) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET
Company Participants
Bobby Gaspar - CEO
Braden Parker - Chief Commercial Officer
Frank Thomas - President & COO
Leslie Meltzer - Chief Medical Officer
Conference Call Participants
Brendan Smith - Cowen and Company
Dae Gon Ha - Stifel, Nicolaus & Company
Pete Stavropoulos - Cantor Fitzgerald & Co.
David Hoang - SMBC
Tessa Romero - JPMorgan Chase & Co/
Operator
Welcome to the Orchard Therapeutics Q1 2022 Earnings Conference Call. My name is John. I'll be operator for today's call. During the question-and-answer session, if you do have a question, pre-1 on your touchtone phone. I will now turn the call over to Bobby Gaspar.
Bobby Gaspar
Hello, everyone, and welcome to Orchard Therapeutics First Quarter 2022 Financial Results and Corporate Update Webcast. I'm CEO and Co-Founder, Bobby Gaspar. Before we get started, I want to remind everyone that this presentation contains forward-looking statements. Please refer to the slide and our latest SEC filings for more information.
I have 3 colleagues joining me on today's call. Braden Parker, our Chief Commercial Officer, is joining us to highlight the success we've recently had expanding commercial access for Libmeldy. Frank Thomas, President and Chief Operating Officer, will review our financial results for the quarter. Leslie Meltzer, our Chief Medical Officer, will also be joining for Q&A.
In March, we spoke about our decision to strategically prioritize the focus of our platform to synergistic indications where we believe HSC gene therapy is scientifically and clinically differentiated from where it can deliver the most value. Through the insights we've gained for many years of scientific and clinical development in this field, we believe indication selection in our space is paramount, and this is what is driving our strategic approach and decision-making. Firstly, we want to focus where the HSC approach has differentiated itself scientifically and clinically, that is in neurodegenerative conditions like MLD, where the migration of gene-modified HSCs into the CNS is key to delivering the gene where it is needed.
With Vamed, we have seen how focusing in this area can lead to clinical benefit, regulatory approval and increasingly commercial success. Throughout the start of 2022, Orchard has built sustained commercial momentum for Libmeldy as the first HSC gene therapy with meaningful reimbursement coverage in Europe. We are extremely pleased by the recognition of Libmeldy value commensurate with its clinical impact, which is reflected in the published net price of EUR 2.4 million attained in Germany and which is indicative of our agreements throughout the region.